The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL
Why the rapid development of new drugs poses new challenges
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure
Anas Younes et al.
'Off the shelf' virus-specific T cells